Structure of Elastase CAS 9004-06-2

Iden­ti­fi­ca­tion

CAS Number

9004-06-2

Name

Elas­tase

Syn­onyms

9-Acrid­i­­namine, N-heptyl-1,2,3,4-tetrahydro-6-methoxy- [ACD/​Index Name]
N-Heptyl-6-methoxy-1,2,3,4-tetrahydro-9-acridinamin [Ger­man] [ACD/IUPAC Name]
N-Heptyl-6-methoxy-1,2,3,4-tetrahydro-9-acridinamine [ACD/IUPAC Name]
N-Heptyl-6-méthoxy-1,2,3,4-tétrahydro-9-acridinamine [French] [ACD/IUPAC Name]
N-heptyl-6-methoxy-1,2,3,4-tetrahydroacridin-9-amine
1,2,3,4-Tetrahydro-N-heptyl-6-methoxy-9-acridinamine
187960-40-3 [RN]
9004-06-2 [RN]
9-Acrid­i­­namine, 1,2,3,4-tetrahydro-N-heptyl-6-methoxy-
9-Heptylamino-6-methoxy-1,2,3,4-tetrahydroacridine
Elas­tase
Heptyl-(6-methoxy-1,2,3,4-tetrahydro-acridin-9-yl)-amine
N-HEPTYL-3-METHOXY-5,6,7,8-TETRAHY­DROACRIDIN-9-AMINE
Tacrine Ana­logue 21

SMILES

CCCCCCCNc1c2ccc(cc2nc3c1CCCC3)OC

Std­InChI

InChI=1S/C21H30N2O/c1-3-4-5-6-9-14-22-21-17-10-7-8-11-19(17)23-20-15-16(24-2)12-13-18(20)21/h12-13,15H,3-11,14H2,1-2H3,(H,22,23)

Std­InChIKey

JLH­FZC­NZU­U­J­­GRC-UHF­F­­FAOYSA-N

Mol­e­c­u­lar Formula

C21H30N2O

Mol­e­c­u­lar Weight

326.476 

MDL Number

MFCD00130997

Prop­er­ties

Appear­ance

Almost white or yel­low­ish powder

Safe­ty Data

RIDADR 

NONH for all modes of transport

WGK Germany

3

Spec­i­fi­ca­tions and Oth­er Infor­ma­tion of Our Elas­tase CAS 9004-06-2

Source

Porcine pan­creas.

Process

Elas­tase is extract­ed from healthy porcine pancreas.

Test ItemsCP
Char­ac­tersAlmost white or yel­low­ish powder
Iden­ti­fi­ca­tionCon­forms
Loss on drying≤ 8.0%(60℃ Dry in Vac­u­um, 4h)
Residue on ignition≤ 2.0%
Heavy met­al≤ 25ppm
Activ­i­ty≥ 30 unit/​mg
Micro­bial Impurities
TAMC≤ 1000cfu/​g
TYMC≤ 100cfu/​g
E.coliCon­forms

Shelf Life

1 year

Stor­age

Store at -20℃ for long time.

Known Appli­ca­tion

Elas­tase prepa­ra­tions are main­ly used to improve abnor­mal lipid metab­o­lism in serum and tis­sues, pro­mote the dis­sim­i­la­tion and excre­tion of cho­les­terol in the liv­er ; increase the activ­i­ty of lipase, pro­mote neu­tral fat and lipopro­tein, espe­cial­ly very low den­si­ty lipopro­tein and low den­si­ty Lipopro­tein metab­o­lism, can inhib­it the occur­rence of ath­er­o­scle­ro­sis and inhib­it exper­i­men­tal liv­er fibro­sis and fat formation.

This prod­uct is devel­oped by our R&D com­pa­ny Ulcho Bio­chem­i­cal Ltd (http://​www​.ulcho​.com/).

Quick Inquiry

Fill out our inquiry form and one of our experts will be in touch with you shortly.

























    Please prove you are human by select­ing the flag.